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Abstract
Thymus- and activation-regulated chemokine (TARC) in
serum/plasma associates with the disease activity of atopic
dermatitis (AD), and is a promising tool for assessing the
response to the treatment of the disease. TARC also exists
within  platelets,  with  elevated  levels  detectable  in  AD
patients. We examined the effects of pre-analytical factors
on the quantitation of TARC in human EDTA plasma. TARC
levels in platelet-free plasma were significantly lower than
those  in  platelet-containing  plasma.  After  freeze-thaw,
TARC levels increased in platelet-containing plasma, but
remained unchanged in platelet-free plasma, suggesting
TARC was released from the platelets during the freeze-
thaw process. In contrast, TARC levels were stable in serum
independent of freeze-thaw. These findings underscore the
importance of pre-analytical factors to TARC quantitation.
Plasma TARC levels should be measured in platelet-free
plasma  for  accurate  quantitation.  Pre-analytical  factors
influence the quantitation, interpretation, and implementa‐
tion of circulating TARC as a biomarker for the develop‐
ment of AD therapeutics.
Keywords Pharmacodynamic biomarker, Pre-analytical
factors, Platelet-free plasma, Platelet-containing plasma,
Freeze-thaw, Thymus, Activation-regulated chemokine,
Atopic dermatitis
1. Introduction
The hallmark of inflammation is the infiltration of specific
leukocyte subsets from the blood into the affected tissue [1].
Chemokines, which are small (8–10 kDa) secreted proteins
and their receptors expressed on the cell surface, orches‐
trate the guided migration of leukocytes to inflammatory
sites. Thymus- and activation-regulated chemokine
(TARC/CCL17) is a high-affinity ligand for CC chemokine
receptor 4 (CCR4), as well as being a Th2 type, pro-allergic
secreted chemokine. TARC serves in the recruitment and
migration of CCR4-expressing cells, such as Th2 cells,
cutaneous leukocyte-associated antigen (CLA)+ skin-
homing T cells, and CD25+ T suppressor cells [2]. It is closely
related to the pathogenesis of allergic diseases with the
accumulation of Th2 lymphocytes in the inflammatory
regions. In inflamed skin lesions, TARC acts on CCR4 at the
endothelial surface to promote vascular recognition for
subsequent cellular localization [3]. TARC is constitutively
expressed in the thymus [4], and is also present in mono‐
cyte-derived dendritic cells [5–7], endothelial cells [8], and
epidermal keratinocytes [9].
Circulating levels of TARC have been associated with
allergic skin diseases such as atopic dermatitis (AD),
contact dermatitis, and psoriasis, in addition to asthma [10]
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and epilepsy [11], but not allergic respiratory diseases such
as allergic rhinitis and allergic asthma [12–14]. Elevated
levels of TARC have been reported in the serum of patients
with AD, compared to that of healthy control subjects [12–
16]. Similar observations have also been reported in the
plasma of AD patients, compared to that of healthy control
subjects [15, 16]. Moreover, the plasma or serum levels of
TARC from AD patients correlated significantly with the
severity of the disease, as classified by the objective
SCORAD score [17, 18]. Thus, plasma/serum TARC is a
disease activity marker for AD. Furthermore, plasma or
serum levels of TARC from AD patients decreased after
treatment, in accordance with the improvement of clinical
symptoms [12–15, 19]. Therefore, plasma/serum TARC can
also be utilized as a pharmacodynamic (PD) marker to
assess disease pathway engagement in the clinical devel‐
opment of AD therapeutics.
In blood, TARC also exists within platelets. Platelets from
AD patients contain higher levels of TARC than those
found in healthy control subjects [15]. Consistent with the
finding of the presence of TARC in platelets, serum TARC
levels were much higher than those in plasma, owing to the
release of TARC from the platelets during coagulation in
serum preparation [15, 16]. Platelets may represent the
predominant source of TARC in circulation, and platelet
rupture, aggregation, or activation may affect levels of non-
cell-associated TARC in blood. Thus, the alteration of
platelets post-phlebotomy would artificially increase the
levels of non-cell-associated TARC in blood. Although pre-
analytical conditions may influence circulating TARC
levels significantly, they have not been investigated
thoroughly for the measurement of this marker.
In this article, we describe the effects of pre-analytical
factors on TARC quantitation in human EDTA plasma,
including the method for EDTA plasma preparation and
plasma sample handling prior to sample analysis. Our
observations underscore the importance of the influence of
pre-analytical factors in clinical biomarker quantitation,
interpretation, and implementation in drug development.
2. Material and Methods
2.1 Ethical conduct of research
The authors state that they have obtained appropriate
institutional review board approval, or have followed the
principles outlined in the Declaration of Helsinki, for all
human or animal experimental investigations. In addition,
for investigations involving human subjects, informed
consent has been obtained from the participants involved.
2.2 Reagents
Recombinant human TARC protein was purchased from
R&D Systems, Inc. (Minneapolis, MN, USA; Catalogue
Number: 364-DN). The human TARC ultra-sensitive kit
was purchased from Meso Scale Discovery (MSD) (Rock‐
ville, USA; Catalogue Number: K151BGC-2). The kit was
supplied with cytokine panel 2 ultra-sensitive plate
(Catalogue Number: N45016A-1); human TARC detection
antibody (Catalogue Number: D21BG-3); cytokine panel 2
calibrator blend (Catalogue Number: C0016-2); Diluent 2
(Catalogue Number: R51BB-3); Diluent 3 (Catalogue
Number: R51BA-5); and MSD Read Buffer T (4x) (Cata‐
logue Number: R92TC-3). DPBS (Dulbecco’s phosphate-
buffered saline) (1x) was purchased from Mediatech, Inc.
(Manassas, VA, USA; Catalogue Number: 21-031-CV).
Surfact-Amps 20 (10% Tween 20) was purchased from
Thermo Fisher Scientific (Rockford, IL, USA; Catalogue
Number: CAS 9005-64-5). Blocker Casein in PBS (1% (w/v)
casein) was also purchased from Thermo Fisher Scientific
(Catalogue Number: 37528). HBR1 (heterophilic blocking
reagent 1) was purchased from Scantibodies Laboratory,
Inc. (Santee, CA, USA; Catalogue Number: 3KC534-075).
StabilZyme SELECT stabilizer was purchased from
SurModics, Inc. (Eden Prairie, MN, USA; Catalogue
Number: SZ03-1000). Distilled water was purchased from
Life Technologies (Grand Island, NY, USA; Catalogue
Number: 15230-147).
EDTA plasma samples of healthy control subjects were
purchased from Bioreclamation, Inc. (Hicksville, NY,
USA).
2.3 Sample collection
Human plasma and serum samples from apparently healthy
subjects were obtained with informed consent. For plasma
preparation,  whole blood was drawn into lavender top
vacutainer tubes (6 mL, K2EDTA (spray dried), BD #367863).
The  blood  tubes  were  mixed  by  gentle  inversion  10x,
incubated  at  room  temperature  (RT)  for  60  min,  and
subsequently centrifuged at 1500 g for 15 min at RT, or
prepared as described in Figure 3. EDTA plasma samples
were collected, aliquoted, and stored at -80°C. For serum
preparation, whole blood was drawn into red top vacutain‐
er tubes (6 mL, clot-activator- and silicone-coated interior,
BD #367815). The blood tubes were incubated at RT for 30
min, and then centrifuged at 1500 g for 15 min at RT. Serum
samples were collected, aliquoted, and stored at -80°C.
2.4 Freeze-thaw treatment of plasma and serum samples
A freeze-thaw treatment of the plasma or serum samples
was executed using the following procedure. Samples (100
μL per aliquot) were stored at -80°C for at least 4 h. They
were then removed from the -80°C freezer and thawed at
RT for 2 h. After one complete freeze-thaw cycle, samples
were either analysed in the TARC assay or stored at -80°C.
2.5 Preparation of standards and QC samples
Recombinant human TARC protein (one vial, 25 μg) was
reconstituted in 2.5 mL of StabilZyme SELECT stabilizer to
a final concentration of 10 μg/mL. Then 200 μL of 10 μg/mL
TARC was mixed with 199.8 mL of Casein-T (1% Casein
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and 0.05% Tween 20 in PBS) to obtain the TARC standard
stock at 10, 000 pg/mL. The TARC standard stock was
aliquoted and stored at -80°C. Prior to each analysis,
standard samples were prepared by serial dilution of the
TARC standard stock with Casein-T, resulting in a nine-
point standard curve with a range of 1.5–10, 000 pg/mL.
Four sets of quality control (QC) samples (Extra High,
High, Medium, and Low) were prepared by spiking
recombinant human TARC protein into a human plasma
sample purchased from Bioreclamation, Inc. The QC
samples were aliquoted and stored at -80°C.
2.6 TARC ECL assay procedure and sample analysis
All samples (plasma, serum, standards, QC, and blank)
were analysed manually in duplicate on an MSD-kit-
supplied 96-well plate. All reagents were brought to room
temperature prior to analysis. Plasma/serum samples and
QC samples were diluted 1:4 in a [Casein-T + HBR] buffer,
containing 0.4 mg/mL HBR1 in Casein-T (1.2 μg of HBR1
per μL of plasma or serum). A plate with 150 μL Casein per
well was incubated for 1.5 h with vigorous shaking (1000
rpm) at RT. The plate was then washed three times with 200
μL per well of PBS-T (0.05% Tween 20 in PBS). After the
addition of 50 μL Casein-T per well, and 50 μL of standards,
diluted samples, or QC samples, the plate was incubated at
RT for 2 h with vigorous shaking (1000 rpm). Upon
completion of the sample incubation, the plate was washed
with PBS-T buffer three times, and 25 μL of human TARC
detection antibody were added to each well. The plate was
incubated for 2 h with vigorous shaking (1000 rpm) at RT.
The plate was again washed with PBS-T buffer three times.
After the addition of 150 μL of 2x Read Buffer T (1:2 dilution
of 4x Read Buffer T in distilled water) to each well, the plate
was read on the MSD Sector Imager 6000.
2.7 Software and statistical analysis
The MSD DISCOVERY WORKBENCH® analysis software
was used for data acquisition and data analysis. The
standard curve was modelled using a least-squares fitting
algorithm, meaning that signals from standards with
known levels of TARC could be used to calculate the
concentration of TARC in the sample. The software utilized
a four-parameter logistic model and included a 1/Y2
weighting function to determine the mean, standard
deviation (stdev), and % coefficient of variance (%CV).
Back-calculated concentrations and % difference of the
back-calculated concentrations were calculated using
Microsoft Excel.
3. Results and Discussion
3.1 Differential effects of freeze-thaw on TARC quantitation in
human EDTA plasma and serum
During the development of an ultra-sensitive electroche‐
miluminescence (ECL) assay for TARC quantitation in
human EDTA plasma, we observed that increased levels of
TARC were detected after repeated freeze-thaw cycles [20].
We decided to further examine the effects of freeze-thaw
on TARC quantitation in EDTA plasma, and in serum as a
comparison, including freshly prepared plasma and serum
samples without any freeze-thaw. EDTA plasma and
subject-matched serum samples were prepared simultane‐
ously from six apparently healthy subjects following
standard procedures, with low-speed centrifugation at
1500 g to separate blood cells from the plasma or serum.
Aliquots of the freshly prepared plasma or serum samples
were either analysed in the TARC assay immediately after
sample preparation, or frozen and stored at -80°C. After the
freeze-thaw treatment, the fresh frozen samples and fresh
frozen samples following additional freeze-thaw cycles
were also analysed in the TARC assay. A fresh frozen
plasma/serum sample was defined as a plasma/serum
sample that was frozen immediately after sample prepara‐
tion. Therefore, every fresh frozen plasma/serum sample
had already gone through one freeze-thaw cycle prior to
the sample analysis for TARC measurement.
Figure 1 illustrates the effects of freeze-thaw cycles on
TARC quantitation in plasma samples. In general, the
TARC levels in the fresh frozen plasma that had gone
through one freeze-thaw cycle were higher than those in
the fresh plasma without freeze-thaw. Exceptions were
observed in certain subject samples, such as K362 and P287.
In addition, the difference in TARC levels between the fresh
and the fresh frozen plasma was particularly large in some
subjects, such as subject A376. Consistent with our previ‐
ous observations, compared to the fresh frozen plasma,
TARC levels increased in plasma that had gone through
one additional freeze-thaw cycle for all subjects. Further‐
more, increased levels of TARC were detected in plasma
with repeated freeze-thaw cycles, up to at least three
additional cycles.
In contrast to the observations in plasma, in subject-
matched serum, TARC levels remained unchanged
between the fresh and the fresh frozen samples for all
subjects, even after three additional freeze-thaw cycles
(Figure 2). The blood draws for serum and subject-matched
EDTA plasma were performed during the same visit, and
the serum and EDTA plasma samples were prepared at the
same time. Consistent with previous observations, TARC
levels in serum were much higher than those in plasma,
probably owing to the release of TARC from platelets
during coagulation (30 min whole blood incubation at RT)
in serum preparation (compare Figure 1 and Figure 2) [15,
16]. In addition, the comparable levels of TARC detected in
fresh serum and serum that had gone through multiple
freeze-thaw cycles suggested that almost all TARC in the
platelets was released into serum during coagulation;
therefore, TARC levels in fresh serum were much higher
than those in fresh plasma. The large ratio of TARC levels
in serum versus plasma — 4–12 fold in six subjects —
suggested that platelets are the predominant source of
circulating TARC.
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3.2 TARC levels in platelet-free, but not platelet-containing,
EDTA plasma were independent of freeze-thaw
We were intrigued by the differential effects of freeze-thaw
on TARC quantitation in matched EDTA plasma and
serum samples from six individual donors (Figure 1 and
Figure 2). The fact that freeze-thaw induced increased
TARC levels in plasma, but not in serum, led us to hy‐
pothesize that plasma samples may have contained
residual platelets, and that these platelets released TARC
during freeze-thaw and contributed to the increase of
TARC in plasma. The EDTA plasma samples used in these
experiments were prepared following the guidelines of a
standard plasma preparation method (National Cancer
Institute, The Early Detection Research Network (EDRN)
Standard Operating Procedure (SOP) for Collection of
EDTA Plasma, http://edrn.nci.nih.gov/resources/standard-
operating-procedures/standard-operating-procedures/
biological-specimens), with low-speed centrifugation of
whole blood at 1500 g for 15 min. These plasma samples
most likely contained residual platelet cells from the whole
blood. We then investigated the effect of the whole blood
centrifugation speed on TARC levels in plasma. In partic‐
ular, we examined TARC levels in platelet-containing and
platelet-free EDTA plasma samples.
Varo et al. performed a thorough analysis of the prepara‐
tion of platelet-rich and platelet-free plasma, by increasing
the speed of whole blood centrifugation (which gradually
depletes platelets and leucocytes from plasma), and
discovered that at least 2000 g centrifugal force is required
to produce platelet-free plasma samples [21]. Thus, plasma
samples prepared through centrifugation at 1500 g most
likely contain residual platelet cells. In addition, Ivandic et
al. [22] and Halldorsdottir et al. [23] have described two
platelet-free plasma preparation methods, involving whole
blood centrifugation greater than 2000 g. Centrifugation at
high speed, as described in these two methods, did not
shear platelet cells. Here, we prepared EDTA plasma using
three different methods (Figure 3): the standard low-speed
centrifugation method (1500 g), which produces platelet-
containing EDTA plasma (method A), as well as two
additional methods described in the literature, which allow
the preparation of platelet-free EDTA plasma (methods B
and C) [22, 23]. The major difference between these three
methods is centrifugation speed, which determines
whether platelet cells in whole blood are completely
separated from EDTA plasma or not. Additional variables
in EDTA plasma preparation (such as the use of glass
versus plastic collection tubes) could potentially impact the











































Figure 1. Effects of freeze-thaw (F-T) cycles on TARC levels in plasma. TARC levels were quantitated in EDTA plasma samples from six subjects, prepared











































Figure 2. Effects of freeze-thaw (F-T) cycles on TARC levels in serum. TARC levels were quantitated in serum samples from six subjects, prepared by low-
speed centrifugation (1500 g): fresh serum, fresh frozen serum, and fresh frozen serum samples following one, two, or three additional F-T cycles. The blood
draws for the serum and the EDTA plasma (Figure 1) were performed during the same visit.
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study is to compare the effects of platelet-containing and
platelet-free EDTA plasma in TARC quantitation.
 
 
Invert 10 times 
to mix. Incubate 
at RT for 60 min.       
1500 g for 
15 min at 4ºC
(Plasma_1500 g)
2500 g for 
15 min at 4ºC
(Plasma_2500 g)
2790 g for
5 min at RT
(Plasma_2790 g) 
16,000 g for 3 min at RT
(Plasma_2790 g_16,000 g)
A B C
Figure 3. Preparation of platelet-containing and platelet-free EDTA plasma
samples. Venous blood was collected into three purple/lavender top EDTA
vacutainer tubes. After the blood tubes were inverted 10 times to mix
thoroughly, and incubated at room temperature (RT) for 60 min, EDTA
plasma samples were prepared following three methods: (A) centrifugation
of the blood tube at 1500 g for 15 min at 4°C, to generate platelet-containing
EDTA plasma; (B) centrifugation of the blood tube at 2500 g for 15 min at
4°C, to generate platelet-free EDTA plasma [22]; and (C) centrifugation of
the blood tube at 2790 g for 5 min at RT to separate cells from the plasma,
then re-centrifugation of the plasma at 16, 000 g for 3 min at RT to remove
any residual platelets, for platelet-free EDTA plasma [23].
From each of the six apparently healthy subjects, we
collected three tubes of venous blood and prepared three
different types of EDTA plasma samples, following the
methods illustrated in Figure 3: (A) Plasma_1500 g, (B)
Plasma_2500 g, and (C) Plasma_2700 g_16, 000 g. The fresh
frozen plasma samples and the fresh frozen plasma
samples following additional freeze-thaw cycles were
analysed in the TARC assay. Three subjects — A376, K362,
and M003 — participated in this study in addition to the
study of freeze-thaw effects on TARC levels in plasma and
matched serum samples described above. However, the
blood draws for these two studies were five weeks apart.
Thus, the plasma TARC levels of the same subject in these
two studies cannot be compared directly, owing to intra-
subject biological variability.
Figure 4 illustrates the differential effects of three different
EDTA plasma preparation methods on TARC levels from
six apparently healthy subjects. For each plasma prepara‐
tion method, TARC levels in the fresh frozen plasma and
the plasma samples following three additional freeze-thaw
cycles were quantified. Again, in the platelet-containing
EDTA plasma samples (Plasma_1500 g), compared to the
fresh frozen plasma, elevated levels of TARC were ob‐
served in the plasma following repeated freeze-thaw
cycles, for all six subjects. In contrast, TARC levels re‐
mained unchanged (<20% difference) even after at least
three additional freeze-thaw cycles, in platelet-free EDTA
plasma prepared following method C (Plasma_2700 g_16,
000 g). After one additional freeze-thaw cycle, the differ‐
ence between TARC levels in method A (Plasma_1500 g)
and method C (Plasma_2700 g_16, 000 g) was significant
between the six subjects, with a p value of 0.008 determined
by a paired T test. Furthermore, this significant difference
was maintained with an additional second and third freeze-
thaw cycle, with p values of 0.009 and 0.011, respectively.
In the platelet-free EDTA plasma prepared following
method B (Plasma_2500 g), TARC levels increased after one
additional freeze-thaw cycle. These observations suggest
that there was sufficient platelet contamination in the
EDTA plasma prepared by low-speed centrifugation, and
that these platelets released TARC during freeze-thaw,
leading to elevated TARC levels in the plasma after
repeated freeze-thaw cycles. In addition, it is possible that
platelet activation could also contributed to the increased
TARC levels in the EDTA plasma prepared by low-speed
centrifugation although it is unlikely. Therefore, it was
platelet contamination (and perhaps activation) that
caused the TARC accumulation in the stored frozen
plasma.
Furthermore, TARC levels were consistently lower in
samples that underwent high-speed centrifugation in all six
subjects (Figure 4: compare the TARC levels in plasma
prepared by method A and method C). We hypothesize
that this was owing to the elimination of residual platelets
achieved with the 16, 000 g centrifugal force. We recognize
that it is also possible that a higher centrifugal force may
minimize the activation of platelets, and thus the release of
TARC. Similar findings have previously been reported; for
instance, Morita et al. reported that, in EDTA plasma
samples prepared by whole blood centrifugation at 2000 g,
TARC levels were not altered after at least five freeze-thaw
cycles [16], suggesting that there was no or minimal platelet
contamination in these plasma samples. Data from the
freeze-thaw study, however, was not shown in the report
[16], making it difficult to perform a careful comparison
with the results that we observed (Figure 4). Fujisawa et al.
reported TARC levels in EDTA plasma samples prepared
by whole blood centrifugation at 1800 g [15], but unfortu‐
nately the effect of freeze-thaw cycles on the TARC levels
in these plasma samples was not examined.
The use of TARC in clinical studies requires reliable sample
preparation and analytical measurement. Our present
results underscore the importance of the careful removal of
platelets to determine free TARC in blood and to avoid
interference with the ligand derived from the cell-associat‐
ed pools. Plasma prepared in this manner can undergo at
least three freeze-thaw cycles without perturbing the
analysis. It is very important to avoid platelet contamina‐
tion in plasma preparation because variabilities in platelet
abundance, TARC expression in platelet, level of residual
platelets in plasma, and degree of ruptured platelets in
plasma after freeze-thaw can lead to incorrect interpreta‐
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tion of TARC in plasma, the biomarker data in a clinical
study. The assessment of citrated plasma or plasma
collected in CTAD (citrate, theophylline, adenosine, and
dipyridamole) tubes for TARC quantitation is warranted.
Both of these tube types are known to help prevent ex-vivo
platelet activation [22]. Platelets produce a number of pro-
inflammatory mediators during activation; as with TARC,
circulating levels of these mediators are complicated in
platelet-containing plasma. These mediators include
vascular endothelial growth factor (VGEF), which is a
platelet-derived growth factor involved in both angiogen‐
esis and pulmonary capillary permeability [25]; platelet
factor 4 (PF4), which is a cytokine stored in platelets and
released during activation [25]; and soluble CD40 ligand
(sCD40L), which is a trans-membrane protein released
from the platelet in its soluble form during platelet activa‐
tion, and is involved in inflammation and thrombosis [21–
23, 25]. Thus, investigators should be cautious of the choice
of specimen and specimen-processing method when
measuring circulating biomarkers that also exists in
platelets.
4. Conclusions
In this article, we have presented the influence of pre-
analytical factors in the quantitation of circulating TARC
levels. Owing to its presence in platelets, the circulating
levels of this pro-inflammatory chemokine were dramati‐
cally altered in platelet-containing EDTA plasma samples
and were further complicated after repeated freeze-thaw
cycles. Therefore, the choice of specimen type and speci‐
men-handling procedures should be carefully considered
for the measurement of circulating non-cell-associated
TARC. When using TARC as a biomarker to aid the clinical
development of atopic dermatitis therapeutics, the opti‐
mum strategy would be to measure TARC in platelet-free
plasma or serum.
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Figure 4. Differential effects of three different EDTA plasma preparation methods on TARC quantitation in plasma. Plasma samples were prepared by method
A, B, or C, as illustrated in Figure 3, from six apparently healthy subjects: A376, K362, K777, L005, M001, and M003. The TARC levels in the fresh frozen plasma
and in the plasma samples that went through an additional one, two, or three freeze-thaw cycles were quantified.
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